keyword
MENU ▼
Read by QxMD icon Read
search

meningococcal b vaccine

keyword
https://www.readbyqxmd.com/read/28637642/emergency-department-attendance-following-4-component-meningococcal-b-vaccination-in-infants
#1
Sarah Kapur, Thomas Bourke, Julie-Ann Maney, Paul Moriarty
INTRODUCTION: In September 2015, the UK became the first country in the world to introduce the 4-component meningococcal B vaccine(4CMenB) into the routine vaccine schedule for infants. 4CMenB is known to cause fever in infants. Infants presenting with fever, particularly those under 3 months, have a significant risk of serious bacterial infection(SBI). METHOD: Between September 2015 and January 2016, we performed a prospective audit of management of infants between 30 and 180 days attending the regional paediatric emergency department(ED) in Northern Ireland, within 4 days of receiving 4CMenB...
June 21, 2017: Archives of Disease in Childhood
https://www.readbyqxmd.com/read/28630122/eculizumab-blocks-vaccine-induced-opsonophagocytic-killing-of-meningococci-by-whole-blood-from-immunized-adults
#2
Monica Konar, Dan M Granoff
Eculizumab, a humanized anti-complement C5 monoclonal antibody for treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome, blocks the terminal complement pathway required for serum bactericidal activity (SBA). Because treated patients are at >1000-fold increased risk of meningococcal disease, vaccination is recommended, but whether vaccination can protect by opsonophagocytic activity in the absence of SBA is not known. Meningococci were added to anticoagulated blood from 12 healthy adults vaccinated with meningococcal serogroup B and serogroup A,C,W,Y vaccines...
June 19, 2017: Blood
https://www.readbyqxmd.com/read/28624305/durability-of-immunogenicity-and-strain-coverage-of-menbvac-a-meningococcal-vaccine-based-on-outer-membrane-vesicles-lessons-of-the-normandy-campaign
#3
Julien Sevestre, Eva Hong, Valérie Delbos, Aude Terrade, Eric Mallet, Ala-Eddine Deghmane, Ludovic Lemée, Muhamed-Kheir Taha, François Caron
OBJECTIVES: MenBvac® is an outer membrane vesicle (OMV)-based meningococcal vaccine. From 2006 to 2012, it was used to control a clonal B outbreak in Normandy (France). We aimed to analyse the durability of the response against the epidemic strain and coverage beyond the vaccine strain. These data should help to optimize the use of OMV-containing vaccines, such as the new 4CMenB/Bexsero® recombinant vaccine. METHODS: Serum bactericidal activity (SBA) was measured in two cohorts of children who received their first dose of MenBvac® at 1-5years of age and accepted to provide a blood sample either one or four years after a 2+1+1 schedule...
June 14, 2017: Vaccine
https://www.readbyqxmd.com/read/28621647/timeliness-and-completeness-of-routine-childhood-vaccinations-in-children-by-two-years-of-age-in-alberta-canada
#4
Vineet Saini, Shannon E MacDonald, Deborah A McNeil, Sheila W McDonald, James D Kellner, Sarah A Edwards, Victoria Stagg, Suzanne Tough
OBJECTIVES: Assessing timeliness and completeness of vaccine administration is important for evaluating the effectiveness of immunization programs. Few studies have reported timeliness, particularly in Canada. The objective of this study was to examine timeliness of the receipt of vaccination for each routine childhood recommended vaccine by 24 months of age among children in a community-based pregnancy cohort in Calgary, Alberta. METHODS: Survey data from a community-based pregnancy cohort in Alberta were linked to Public Health vaccination records of children (n = 2763)...
June 16, 2017: Canadian Journal of Public Health. Revue Canadienne de Santé Publique
https://www.readbyqxmd.com/read/28599793/a-cross-reacting-material-crm197-conjugate-vaccine-induces-diphtheria-toxin-neutralizing-antibody-response-in-children-and-adolescents-infected-or-not-with-hiv
#5
Giselle P Silva, Rafaela S Santos, Wânia F Pereira-Manfro, Bianca Ferreira, Daniella M Barreto, Ana Cristina C Frota, Cristina B Hofer, Lucimar G Milagres
Anti-diphtheria antibody levels decrease with aging, and frequent booster vaccinations are required to maintain herd immunity. We analyzed the diphtheria toxin neutralizing antibody (DT-Nab) response induced by a conjugate vaccine (meningococcal C polysaccharide-CRM197) in HIV-vertically infected (HI) children and adolescents and healthy controls (HC) with matched age. We report the association of DT-Nab with the bactericidal antibodies to serogroup C meningococcus (MenC). Before vaccination, 21 HI patients (50%) had no protection against diphtheria (≤0...
June 6, 2017: Vaccine
https://www.readbyqxmd.com/read/28592578/bacterial-meningitis-in-finland-1995-2014-a-population-based-observational-study
#6
Aleksandra Polkowska, Maija Toropainen, Jukka Ollgren, Outi Lyytikäinen, J Pekka Nuorti
OBJECTIVES: Bacterial meningitis remains an important cause of morbidity and mortality worldwide. Its epidemiological characteristics, however, are changing due to new vaccines and secular trends. Conjugate vaccines against Haemophilus influenzae type b and Streptococcus pneumoniae (10-valent) were introduced in 1986 and 2010 in Finland. We assessed the disease burden and long-term trends of five common causes of bacterial meningitis in a population-based observational study. METHODS: A case was defined as isolation of S...
June 6, 2017: BMJ Open
https://www.readbyqxmd.com/read/28583305/immunogenicity-and-safety-of-a-new-hexavalent-vaccine-dtap5-ipv-hb-hib-administered-in-a-mixed-primary-series-schedule-with-a-pentavalent-vaccine-dtap5-ipv-hib
#7
Federico Martinón-Torres, Florence Boisnard, Stéphane Thomas, Christine Sadorge, Ray Borrow
DTaP5-IPV-HB-Hib vaccine is a fully-liquid, combination hexavalent vaccine. This phase III, open-label, multicentre study conducted in Spain, evaluated the immune response to all DTaP5-IPV-HB-Hib antigens when the vaccine was used in a mixed hexa/penta/hexa primary series. Infants (who had received one dose of hepatitis B vaccine at birth) received a mixed schedule including DTaP5-IPV-HB-Hib (PRP-OMP conjugate) at 2 and 6months of age, DTaP5-IPV-Hib at 4months, meningococcal serogroup C conjugate (MCC) vaccine at 2 and 4months, and routine rotavirus and pneumococcal vaccination...
June 2, 2017: Vaccine
https://www.readbyqxmd.com/read/28582542/serum-bactericidal-antibody-responses-of-students-immunized-with-a-meningococcal-serogroup-b-vaccine-in-response-to-an-outbreak-on-a-university-campus
#8
Eduardo Lujan, Kathleen Winter, Jillandra Rovaris, Qin Liu, Dan M Granoff
Background.: MenB-4C is a recently licensed meningococcal serogroup B vaccine. For vaccine licensure, short-term efficacy was inferred from serum bactericidal antibody (SBA) titers against three antigen-specific indicator strains, which are not necessarily representative of U.S. disease-causing strains. Methods.: 4923 students were immunized with MenB-4C in response to an outbreak at a university. Serum samples were obtained at 1.5 to 2 months from 106 students who received the recommended 2 doses and 52 unvaccinated students...
June 3, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28581267/characterization-of-oropharyngeal-carriage-isolates-of-neisseria-meningitidis-in-healthy-korean-adolescents-in-2015
#9
Han Wool Kim, Soyoung Lee, Daeho Kwon, Jihei Cha, Jong Gyun Ahn, Kyung Hyo Kim
The meningococcus carriage rate is age-dependent, with a high prevalence in adolescents and young adults. This cross-sectional study aimed to estimate the oropharyngeal carriage rate of meningococcus among healthy Korean adolescents and its relationship with several population characteristics. The survey was conducted from April to May 2015 among 1,460 first-year high-school students in 9 high schools located in Gyeonggi province, Korea. Each student answered a short questionnaire assessing risk factors for carriage, and posterior pharyngeal wall swab samples were obtained...
July 2017: Journal of Korean Medical Science
https://www.readbyqxmd.com/read/28580917/crystal-structures-of-human-fabs-targeting-the-bexsero-meningococcal-vaccine-antigen-nhba
#10
Martina Maritan, Roberta Cozzi, Paola Lo Surdo, Daniele Veggi, Matthew James Bottomley, Enrico Malito
Neisserial heparin-binding antigen (NHBA) is a surface-exposed lipoprotein from Neisseria meningitidis and is a component of the meningococcus B vaccine Bexsero. As part of a study to characterize the three-dimensional structure of NHBA and the molecular basis of the human immune response to Bexsero, the crystal structures of two fragment antigen-binding domains (Fabs) isolated from human monoclonal antibodies targeting NHBA were determined. Through a high-resolution analysis of the organization and the amino-acid composition of the CDRs, these structures provide broad insights into the NHBA epitopes recognized by the human immune system...
June 1, 2017: Acta Crystallographica. Section F, Structural Biology Communications
https://www.readbyqxmd.com/read/28579305/frequent-capsule-switching-in-ultra-virulent-meningococci-are-we%C3%A2-ready-for-a-serogroup-b-st-11-complex%C3%A2-outbreak
#11
Jay Lucidarme, Aiswarya Lekshmi, Sydel R Parikh, James E Bray, Dorothea M Hill, Holly B Bratcher, Steve J Gray, Anthony D Carr, Keith A Jolley, Jamie Findlow, Helen Campbell, Shamez N Ladhani, Mary E Ramsay, Martin C J Maiden, Ray Borrow
The meningococcal ST-11 complex (cc11) causes large invasive disease outbreaks with high case fatality rates, such as serogroup C (MenC) epidemics in industrialised nations in the 1990s and the serogroup W epidemic currently expanding globally. Glycoconjugate vaccines are available for serogroups A, C, W and Y. Broad coverage protein-based vaccines have recently been licensed against serogroup B meningococci (MenB), however, these do not afford universal MenB protection. Capsular switching from MenC to MenB among cc11 organisms is concerning because a large MenB cc11 (B:cc11) outbreak has the potential to cause significant morbidity and mortality...
June 1, 2017: Journal of Infection
https://www.readbyqxmd.com/read/28579170/vaccination-coverage-in-a-cohort-of-hiv-infected-patients-receiving-care-at-an-aids-outpatient-clinic-in-esp%C3%A3-rito-santo-brazil
#12
Lauro Ferreira da Silva Pinto Neto, Julia Vescovi Vieira, Nathália Rossoni Ronchi
This cross-sectional study assessed the immunization status of human immune deficiency virus (HIV)-infected patients receiving care at an outpatient clinic in Brazil. The sociodemographic characteristics, CD4 count and HIV viral load of 281 out of 612 adult outpatients were analyzed. A total of 331 patients were excluded because of no availability of vaccination cards. Chi-square or Fisher's exact test were used. Immunization coverage was higher for diphtheria/tetanus (59.79%) and hepatitis B (56.7%), and lowest for hepatitis A (6...
June 1, 2017: Brazilian Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28573801/meningococcal-b-vaccine-efficacy
#13
David Isaacs
No abstract text is available yet for this article.
June 2017: Journal of Paediatrics and Child Health
https://www.readbyqxmd.com/read/28566335/breadth-and-duration-of-meningococcal-serum-bactericidal-activity-in-healthcare-workers-and-microbiologists-immunized-with-the-menb-fhbp-vaccine
#14
Eduardo Lujan, Elizabeth Partridge, Serena Giuntini, Sanjay Ram, Dan M Granoff
Background. MenB-FHbp is a meningococcal serogroup B vaccine with two Factor H binding protein (FHbp) antigens from subfamilies A and B. For licensure, efficacy was inferred from serum bactericidal antibody (SBA) responses against four reference strains. Only limited information is available on breadth or duration of protective SBA responses against genetically diverse disease-causing strains.Methods. Seventeen healthcare or laboratory workers were immunized with two (N=2) or three (N=15) doses of MenB-FHbp at 0, 2 and 6 months...
May 31, 2017: Clinical and Vaccine Immunology: CVI
https://www.readbyqxmd.com/read/28557743/understanding-the-category-b-recommendation-for-serogroup-b-meningococcal-vaccine
#15
Gary S Marshall, Litjen Tan
No abstract text is available yet for this article.
May 2017: Pediatrics
https://www.readbyqxmd.com/read/28557577/the-next-chapter-for-group-b-meningococcal-vaccines
#16
N Y Wang, A J Pollard
The majority of invasive meningococcal disease (IMD) in the developed world is caused by capsular group B Neisseria meningitidis, however success with vaccination against organisms bearing this capsule has previously been restricted to control of geographically limited clonal outbreaks. As we enter a new era, with the first routine program underway to control endemic group B meningococcal disease for infants in the UK, it is timely to review the key landmarks in group B vaccine development, and discuss the issues determining whether control of endemic group B disease will be achieved...
May 30, 2017: Critical Reviews in Microbiology
https://www.readbyqxmd.com/read/28533054/reduced-schedules-of-4cmenb-vaccine-in-infants-and-catch-up-series-in-children-immunogenicity-and-safety-results-from-a-randomised-open-label-phase-3b-trial
#17
Federico Martinón-Torres, Marco Aurelio P Safadi, Alfonso Carmona Martinez, Pilar Infante Marquez, Juan Carlos Tejedor Torres, Lily Yin Weckx, Edson Duarte Moreira, Ilhem Mensi, Marco Calabresi, Daniela Toneatto
BACKGROUND: This study evaluated the immunogenicity and safety of a licensed meningococcal serogroup B vaccine (4CMenB) administered alone according to reduced schedules in infants or catch-up series in children. METHODS: In this open-label, multicentre, phase 3b study (NCT01339923), infants randomised 1:1:1 received 4CMenB: 2+1 doses at 3½-5-11months or 6-8-11months of age, 3+1 doses at ages 2½-3½-5-11months. Children aged 2-10years received 2 catch-up doses administered 2months apart...
June 16, 2017: Vaccine
https://www.readbyqxmd.com/read/28520709/updated-recommendations-for-use-of-menb-fhbp-serogroup-b-meningococcal-vaccine-advisory-committee-on-immunization-practices-2016
#18
Monica E Patton, David Stephens, Kelly Moore, Jessica R MacNeil
Two serogroup B meningococcal (MenB) vaccines are currently licensed for use in persons aged 10-25 years in the United States. The two vaccines are MenB-FHbp (Trumenba, Pfizer, Inc.) (1) and MenB-4C (Bexsero, GlaxoSmithKline Biologicals, Inc.) (2). In February 2015, the Advisory Committee on Immunization Practices (ACIP) recommended use of MenB vaccines among certain groups of persons aged ≥10 years who are at increased risk for serogroup B meningococcal disease* (Category A) (3), and in June 2015, ACIP recommended that adolescents and young adults aged 16-23 years may be vaccinated with MenB vaccines to provide short-term protection against most strains of serogroup B meningococcal disease (Category B(†)) (4)...
May 19, 2017: MMWR. Morbidity and Mortality Weekly Report
https://www.readbyqxmd.com/read/28505234/increased-risk-for-meningococcal-disease-among-men-who-have-sex-with-men-in-the-united-states-2012-2015
#19
Temitope A Folaranmi, Cecilia B Kretz, Hajime Kamiya, Jessica R MacNeil, Melissa J Whaley, Amy Blain, Mike Antwi, Marie Dorsinville, Massimo Pacilli, Shamika Smith, Rachel Civen, Van Ngo, Kathleen Winter, Kathleen Harriman, Xin Wang, Virginia B Bowen, Manisha Patel, Stacey Martin, Lara Misegades, Sarah A Meyer
Background: Several clusters of serogroup C meningococcal disease among men who have sex with men (MSM) have been reported in the United States in recent years. The epidemiology and risk of meningococcal disease among MSM is not well-described. Methods: All meningococcal disease cases among men aged 18-64 years reported to the National Notifiable Disease Surveillance System between January 2012 and June 2015 were reviewed. Characteristics of meningococcal disease cases among MSM and men not known to be MSM (non-MSM) were described...
May 13, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28498097/the-asplenic-patient-post-insult-immunocompetence-infection-and-vaccination
#20
Brandon Dionne, Walter Dehority, Meghan Brett, Thomas R Howdieshell
BACKGROUND: Splenic injury can occur through multiple mechanisms and may result in various degrees of residual immunocompetence. Functionally or anatomically asplenic patients are at higher risk for infection, particularly with encapsulated bacteria. Vaccination is recommended to prevent infection with these organisms; however, the recommendations are routinely updated, and vaccine selection and timing are complex. METHODS: Review of the pertinent English-language literature, including the recommendations of the U...
May 12, 2017: Surgical Infections
keyword
keyword
61786
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"